| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22026 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Is indicated as monotherapy for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. |
| Assessment Process | |
| Rapid review commissioned | 22/04/2022 |
| Rapid review completed | 01/06/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/07/2022 |
| Pre-submission consultation with Applicant | 06/09/2022 |
| Full submission received from Applicant | 23/03/2023 |
| Preliminary review sent to Applicant | 08/12/2023 |
| NCPE assessment re-commenced | 18/01/2024 |
| Factual accuracy sent to Applicant | 11/04/2024 |
| NCPE assessment re-commenced | 18/04/2024 |
| NCPE assessment completed | 29/04/2024 |
| NCPE assessment outcome | The NCPE recommends that pembrolizumab (Keytruda®) be considered for reimbursement, for this indication, if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
